Navigation Links
Bladder cancer patients rarely receive recommended care
Date:7/10/2011

A new study has found that almost all patients with high-grade noninvasive bladder cancer do not receive complete care as recommended by current guidelines. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that efforts are needed to identify and overcome barriers to providing optimal care to patients with bladder cancer.

High-grade noninvasive bladder cancer has up to a 70 percent chance of recurring after treatment and up to a 50 percent chance of progressing to a more invasive tumor. Effective treatment for patients with high-grade noninvasive bladder cancer is critical. If the bladder tumor recurs and remains noninvasive, patients must undergo multiple operations; if it recurs and progresses to an invasive cancer, patients are at risk of having the cancer spread, and they may need to have their bladder removed and undergo radiation and chemotherapy treatments.

Medical guidelines advocate for delivering anticancer chemotherapy directly into the bladder (intravesical therapy) in order to minimize recurrence and progression of bladder cancer. They also recommend an intense follow-up schedule involving the use of a scope to evaluate the bladder (cytoscopy) and a urine test (cytology) every three months. To see whether patients are actually receiving this recommended care, Karim Chamie, MD, MSHS of the University of California Los Angeles led a team of researchers from UCLA's Jonsson Comprehensive Cancer Center that analyzed information on 4,545 patients diagnosed with high-grade noninvasive bladder cancer from 1992 to 2002 whose data were contained in the Surveillance, Epidemiology and End Results (SEER)-Medicare database, which links cancer registry information to a master file of Medicare enrollment. "To our surprise, out of the 4,545 patients, only one received care that was compliant with all the guideline recommendations," said Dr. Chamie. "In addition, nearly half of urologists have not performed at least one cystoscopy, one cytology, and one instillation of intravesical therapy for any given patient in the first two years after diagnosis."

The researchers measured whether patients' age, race, socioeconomic status, severity of other medical conditions, and extent of their bladder cancer contributed to the low compliance rate with guideline recommendations. They discovered that these patient-level factors had little effect. Rather, the most important predictor of whether a patient underwent recommended care was the physician. Additional studies are needed to identify why the vast majority of physicians are not following medical guidelines related to bladder cancer.

Based on these findings, "one would deduce that more than 99 percent of patients with high-risk bladder cancer are not receiving recommended care. This is significantly less than what most patients with bladder cancer, their physicians, and policy makers believe is happening," said Dr. Chamie. "We hope that shedding light on the level of discordance between ideal and routine care will prompt policy makers to modify reimbursement policies or support quality-improvement initiatives in the future."


'/>"/>

Contact: Jennifer Beal
healthnews@wiley.com
44-012-437-70633
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Costly tests may not help detect bladder cancer recurrence, M. D. Anderson study finds
2. San Francisco Firefighters: Increased Risk for Bladder Cancer – Testing Underway
3. Meat Lovers Face Greater Risk of Bladder Cancer
4. Unmet expectations and smoking prove key factors in quitting bladder medication
5. Clue to switch of bladder cancer from locally contained to invasive found by Jefferson scientists
6. Study finds 2 sling surgeries equally effective for bladder control in women
7. Vitamins Fail to Protect Men Against Bladder Cancer
8. Radiation does not improve survival for rare, invasive bladder cancer
9. Removing Gallbladder Sooner Cuts Costs, Readmissions
10. NOSCAR announces first NOTES transoral and transvaginal gallbladder removals performed as part of US multicenter human trial
11. Certain meat components may increase bladder cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary to popular ... violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright and his ... in violence in the United States. The study, Trends in Fighting and ...
(Date:4/21/2017)... PA (PRWEB) , ... April 21, 2017 , ... Dudnyk ... new identity emphasizes the agency’s conviction that the full potential of specialty and orphan ... are equally appreciated and aligned. , “The Unifying Effect is at the heart ...
(Date:4/21/2017)... ... 21, 2017 , ... Crossover Symmetry , an evidence ... active lifestyle company that provides Human Performance Training and education to tactical athletes. ... responders, military officers and others in service through the development and conditioning of ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... world leaders in hopes of squashing a global crisis with solution to peace plan. Yisrayl ... to work because the plan is given by the Creator Himself. , Yisrayl says ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... April 18, 2017  Astute Medical, Inc., developer of ... to be presented at the 2017 National Kidney Foundation ... and continues through April 22. Physicians will present data ... to assess risk for acute kidney injury (AKI) during ... (ADHF). Elevated levels of TIMP-2 and ...
Breaking Medicine Technology: